Amplify Energy is a holding company. Through its wholly-owned subsidiary, Midstates Petroleum Company LLC, the company is an independent exploration and production company focused on the application of drilling, completion and production operations techniques in oil and liquids basins in the onshore U.S. The company's operations are focused on exploration and production activities in the Mississippian Lime. The company's Mississippian Lime assets are located in Oklahoma and target the Mississippian Lime formation.

AstroNova designs, develops, manufactures and distributes a range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats. The company's business consists of two segments, Product Identification (PI) and Test & Measurement (T&M). The PI segment includes specialty printing systems sold under the brand names QuickLabel?, TrojanLabel? and GetLabels?. The company's T&M segment includes the company's line of aerospace flight deck printers and test and measurement data acquisition systems sold under the AstroNova? brand name.

BCB Bancorp is a bank holding company. Through its subsidiary, BCB Community Bank (the Bank), the company provides Federal Deposit Insurance Corporation (FDIC)-insured deposit products and invests funds held in deposit accounts at the Bank, together with funds generated from operations, in loans and investment securities. The company also provides loans to its customers, including commercial and multi-family real estate loans, one- to four-family mortgage loans, commercial business loans, construction loans, home equity loans, and consumer loans. The company's deposit instruments include demand, negotiable order of withdrawal, savings and club accounts, money market accounts, and term certificate accounts.

Citizens is an insurance holding company. Through its insurance subsidiaries, the company provides insurance products. The company's main insurance operations include: U.S. Dollar-denominated ordinary whole life insurance and endowment policies mainly sold to foreign residents, located principally in Latin America and the Pacific Rim; ordinary whole life insurance policies to middle income households focused on the Midwest, Mountain West and southern U.S.; and final expense and limited liability property policies to middle and lower income households in Louisiana, Mississippi and Arkansas. The company has two segments: Life Insurance and Home Service Insurance. The company also has Other Non-Insurance Operations.

Codexis discovers, develops and sells proteins to its clients. The company has two segments: Performance Enzymes, which uses its technology to develop enzymes for customers using next generation sequencing and polymerase chain reaction for in vitro molecular diagnostic and molecular biology research applications; and Novel Biotherapeutics, in which it has announced a global development, option and license agreement with Societe des Produits Nestle S.A. to develop CDX-6114, its own orally administrable enzyme therapeutic candidate for the potential treatment of phenylketonuria. The company's products include protein catalysts, chemical intermediates and Codex? biocatalyst panels and kits.

Full House Resorts owns, leases, operates, develops, manages, and/or invests in casinos and related hospitality and entertainment facilities. The company manages its casinos based on geographic regions within the U.S. The casino/resort operations includes four segments: the Silver Slipper Casino and Hotel (Hancock County, MI); Bronco Billy's Casino and Hotel (Cripple Creek, CO); the Rising Star Casino Resort (Rising Sun, IN); and the Northern Nevada segment, consisting of the Grand Lodge Casino (Incline Village, NV) and Stockman's Casino (Fallon, NV).

Immunic is a biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase; IMU-935 is an inverse agonist of RORgt; and IMU-856 targets the restoration of the intestinal barrier function. The company's main development program, IMU-838, is in Phase 2 clinical development for relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional Phase 2 trial considered in Crohn's disease.

IRIDEX is an ophthalmic medical technology company focused on the development and commercialization of products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Certain of the company's laser products are powered by its proprietary MicroPulse? technology. The company provides three product categories: laser consoles; delivery devices which are optical-mechanical products that mount to ophthalmologist's diagnostic equipment and transmit the laser; and single-use disposable probes that transmit the laser light to a targeted region within the inside of an eye.

Martin Midstream Partners has a set of operations focused primarily in the United States Gulf Coast region. The company's primary business segments are: Terminalling and Storage, which provides storage, refining, blending, packaging, and handling services for producers and suppliers of petroleum products and by-products; Transportation, which operates a fleet of both land transportation and marine transportation assets that transport petroleum products and by-products, petrochemicals, and chemicals; Sulfur Services, which transports molten sulfur and fertilizer products; and natural gas liquids (NGL), which distributes NGLs that it primarily purchases from refineries and natural gas processors.

Rafael Holdings owns interests in commercial real estate assets and clinical stage pharmaceutical companies. The company's business consists of two reportable segments: Real Estate and Pharmaceuticals. The commercial real estate holdings consist of the building in Newark, NJ that serves as headquarters for the company and certain affiliated entities, car public garage, an office/data center building in Piscataway, NJ and a portion of a building in Israel. The pharmaceutical holdings include Rafael Pharmaceuticals, Inc., which is a clinical-stage, oncology-focused, pharmaceutical company and LipoMedix Pharmaceuticals Ltd., which is a clinical-stage oncological pharmaceutical company based in Israel.

Tilly's is a retailer of casual apparel, footwear and accessories for young men, young women, boys and girls. The company's stores are located in malls, lifestyle centers, power centers, community centers, outlet centers and street-front locations. Customers may also shop online, where the company features the same assortment of product as is carried in its stores, supplemented by additional online-only styles. The company provides a mix of merchandise for young men, young women, boys and girls across the apparel, footwear and accessories categories. The company's apparel merchandise includes branded, fashion, and core styles for tops, outerwear, bottoms, and dresses.

Ultralife provides products and services ranging from power solutions to communications and electronics systems. The company has two operating segments: Battery and Energy Products, which includes lithium nine-volt, cylindrical, thin cell and other non-rechargeable batteries, in addition to rechargeable batteries, uninterruptable power supplies, charging systems and accessories; and Communications Systems, which includes radio frequency amplifiers, power supplies, cable and connector assemblies, amplified speakers, equipment mounts, case equipment, man-portable systems, integrated communication systems for fixed or vehicle applications and communications and electronics systems design.

Universal Electronics develops control and sensor technology solutions and manufactures a line of pre-programmed and universal remote control products, audio-video accessories, and intelligent wireless security and smart home products. The company provides subscription broadcasting providers with its universal remote control devices and integrated circuits, on which its software and device code libraries are embedded. The company also sells integrated circuits, on which its software and device control code libraries are embedded, and licenses its device control database to original equipment manufacturers that manufacture televisions, digital audio and video players, streamer boxes, among others.

Vera Bradley is a designer of women's handbags, luggage and travel items, fashion and home accessories, and gifts. The company sells its products through two reportable segments: Direct and Indirect. The Direct business consists of sales of Vera Bradley products through the company's full-line and factory outlet stores, verabradley.com, the company's online outlet site, direct-to-consumer eBay sales, and the company's annual outlet sale in Fort Wayne, IN. The Indirect business consists of sales of Vera Bradley products to specialty retail locations, as well as department stores, national accounts, third party e-commerce sites, third-party inventory liquidators, and sales generated through licensing agreements.

Village Farms International produces, markets and sells tomatoes, bell peppers and cucumbers, with its primary operations in the United States and Canada. Co.'s products are marketed and distributed under its Village Farms® brand name and other brand names, primarily to retail supermarkets and dedicated fresh food distribution companies. Co. also markets and distributes produce under exclusive arrangements for other greenhouse producers primarily located in British Columbia, central Mexico and the north eastern part of the United States.

Y-mAbs Therapeutics is a biopharmaceutical company focused on the development and commercialization of antibody-based therapeutic products for the treatment of cancer. The company has a range of product pipeline, including two pivotal-stage product candidates: naxitamab and omburtamab, which target tumors that express GD2 and B7-H3, respectively. The company is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma (NB), and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, from NB.